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EDITORIAL
Nature and nurture on phenotypic variability of autosomal
dominant polycystic kidney disease
Autosomal-dominant polycystic kidney disease
(ADPKD) is the most common Mendelian disor-
der of the kidney, affecting all ethnic groups worldwide
with an incidence of ∼1 in 500 to 1000 births. It is
characterized by progressive formation and enlargement
of renal cysts, typically leading to chronic renal failure by
late middle age. Other manifestations of this disorder,
such as cyst formation in nonrenal organs, hypertension,
cardiac valvular defects, colonic diverticulosis, and
intracranial arterial aneurysms, accompany the renal
disease variably. Overall, ADPKD accounts for ∼5%
to 8% of end-stage renal disease (ESRD) [1, 2]. Two
disease genes (PKD1 and PKD2) have been identified
and, respectively, account for ∼85% and ∼15% of cases
in the Caucasian population [2]. Polycystin 1 and 2,
the gene products of PKD1 and PKD2, are plasma
membrane proteins that form components of a novel
multifunctional signaling pathway [1]. Polycystin 1 is
predicted to have a receptor-like structure, and may be
involved in cell-cell and/or cell-matrix interaction. By
contrast, polycystin 2 is thought to function as a subunit
of a nonselective cation channel. Both proteins have
been shown to interact in vitro through their cytoplasmic
region, and transmit fluid-flow mediated mechanosen-
sation by the primary cilium in renal epithelium [1, 3].
Disruption of the function of polycystin 1 or 2 may cause
ADPKD, owing to the inability of the tubular epithelial
cells to sense mechanical cues that normally regulate
tissue morphogenesis [3].
A striking feature of ADPKD is its phenotypic variabil-
ity. In particular, renal disease progression in ADPKD is
highly variable, with the age of ESRD ranging from child-
hood to old age [1, 2]. Recent studies have shown that
genomic deletion of PKD1 and TSC2, or bilineal inher-
itance of heterozygous PKD1 and PKD2 mutations, can
result in earlier and more severe renal disease in a small
number of patients [2]. For the majority of cases, however,
the gene locus confers a major effect for interfamilial re-
nal disease variability: patients from PKD1 families have
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an earlier onset of ESRD than patients from PKD2 fam-
ilies [median age at ESRD: 53 (95%CI: 51.2-54.8) vs. 69
(95%CI: 66.9-71.3)] years, respectively) [4]. A gender ef-
fect on renal survival (i.e., absence of ESRD) favoring
the female patients is also evident in type 2, but in not
type 1 ADPKD [4–6]. By contrast, a weak allelic effect
(based on the 5’ vs. 3’ location of the germline mutations)
on renal disease progression may exist for type 1 [5], but
not type 2 ADPKD [6]. Additionally, significant intrafa-
milial renal disease variability has been well documented
in both type 1 and 2 ADPKD [5–7]. These latter find-
ings suggest that renal disease progression in ADPKD
may be modified by genetic, environmental, and stochas-
tic factors independent of the germline PKD mutations.
The existence of modifier genes for ADPKD is further
supported by a recent study documenting a larger intra-
class correlation coefficient for the age of onset of ESRD
in 9 monozygotic twin pairs compared to 56 sibships [8].
Nevertheless, the magnitude of the modifier gene effect
for renal disease progression in ADPKD is not currently
known.
In this issue of Kidney International, Fain et al [9] re-
ported their quantitative genetic analysis on a number of
phenotypic traits from 315 affected relatives in 83 multi-
plex PKD1 families. Using the variance components anal-
ysis, they estimated the heritability (i.e., the proportion of
variance due to modifier genes) of these traits. They found
that inherited difference in modifier genes accounted for
18% to 59% of the variance of the traits examined. Im-
portantly, they found that modifier genes accounted for
∼32% of the variance for creatinine clearance (Ccr) and
43% to 50% of the variance for age of ESRD. Addi-
tionally, modifier genes accounted for a significant pro-
portion of the variances for other surrogate measures of
renal and hepatic cystic disease. The main strengths of this
study included the use of a robust research methodology
for within-family comparisons in a well-characterized co-
hort of PKD1 families, which controlled for differences
in age, gender, gene locus, and allelic effects. However,
there were some limitations, as well. First, there was a
selection bias for younger and less severely affected pa-
tients in this study. As a result, the median age of ESRD
in the study cohort was older than that from 2 recent
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PKD1 studies (61 vs. 53 and 54 years, respectively) [4, 5].
Consequent to the enrichment of younger patients whose
disease has not been given a chance to manifest fully, the
current study may underestimate the true magnitude of
the modifier gene effect. Second, a number of trait values
in the current study were not normally distributed. Viola-
tion of this assumption in the variance components analy-
sis may impact the precision of the heritability estimates.
Thus, the extreme kurtosis in the distribution of serum
creatinine values could affect the reliability of its heri-
tability estimate compared to other related traits, such
as Ccr and age of ESRD. Nevertheless, the heritability
estimates on Ccr and age of ESRD in the current study
are generally concordant with another recent study of
largely unselected PKD1 patients using similar study de-
sign [10]. While differences in methodology preclude di-
rect comparisons between these 2 studies, they do support
the notion that both genetic and environment modifiers
play a significant role for renal disease progression of
ADPKD.
Where do we go from here? I believe that a formal
and systematic search for genetic modifiers of renal dis-
ease progression in ADPKD is justifiable at this time.
However, the identification of these modifier genes will
be challenging because of the polygenic nature of this
complex trait [11]. The best scenario that one can hope
for is that a few moderately strong gene loci account for
most of the modifier effect. Even under this scenario, a
large patient and family resource will still be required to
ensure adequate power in the study [9, 10], which under-
pins the need for large-scale international collaboration.
The identification of major modifier genes in ADPKD
is expected to improve our current understanding of the
relevant molecular pathways, as well as environmental
factors (for gene-environment interaction) that promote
progression of this renal disease. Such knowledge is es-
sential for future development of individualized patient
risk prediction and mechanism-based therapeutics for
ADPKD—a promise of molecular medicine.
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